Biopharma Daily Stock Updates - 07/16/21

$XBI $125.9 0.0%

---

Covid Updates

$BNTX +4.7% U.S. FDA Grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 Vaccine. source

$IBIO +0.8% iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate. source

Pipeline Updates

$KDMN +20.6% U.S. FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD). source

$FATE +2.4% Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma. source

$HCM +3.7% HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency. source

$FGEN -42.2% FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease. source

Financial Updates

$ENDP +1.7% Endo Comments on Tennessee Appeals Court Orders. source

$ATOS -19.9% Atossa in selloff for second straight session after sharp run-up this year. source

---

Posted by FS